CEPI (Coalition for Epidemic Preparedness Innovations)’s Post

I’m proud to announce the initiation of a rapid sterility project, under the CEPI Analytical Innovation CfP. This one aims to reduce the sterility test to under 72 hrs allowing faster release of biological vaccine products.

United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033 United States Vaccines Market Size and Trends The United States vaccines market size was valued at USD 29.5 billion in 2024 and is projected to hit around USD 60 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025 to 2033. United States Vaccine Market Growth Drivers  One of the foremost factors influencing the expansion of the vaccine market in the United States is the rising prevalence of infectious diseases. With the emergence of new pathogens and variants, the demand for effective vaccines has surged. Additionally, advancements in biotechnology and genetic research are leading to the development of more effective and targeted vaccine formulations. Another critical catalyst is the robust investment in vaccine research and development. Government agencies and private organizations alike are funneling funds into vaccine projects, accelerating the pace of innovation. Moreover, regulatory support and streamlined approval processes have encouraged manufacturers to bring new vaccines to market more quickly. More Details @ https://lnkd.in/dTfaMzEP #vaccine #covid #coronavirus #vaccination #health #vaccines #pandemic #corona #trump #pfizer #lockdown #covidvaccine #healthcare #news #freedom #medicine #virus #moderna #science #flu #covidvacccine #india #influenza #memes #vaccineswork #doctor #staysafe #vaccinated #immunization #vaksin

BioMaP-Consortium Launches Critical Initiative to Onshore Viral Hemorrhagic Fever Vaccine Manufacturing   The Biopharmaceutical Manufacturing Preparedness (BioMaP) Consortium has released a Request for Project Proposals (RPP-26-10-VHF) focused on establishing domestic manufacturing capabilities for life-saving viral hemorrhagic fever vaccines. This initiative represents a strategic investment in U.S. biosecurity and pandemic preparedness infrastructure.   Currently, no domestic manufacturing capability exists for vaccines targeting viral hemorrhagic fever viruses such as Marburg and Ebola Sudan. This gap poses significant risks to national health security, particularly given the high mortality rates associated with these pathogens of up to 90% for some filovirus infections.   The U.S. Government is initiating efforts to onshore the manufacturing of novel Vesicular Stomatitis Virus (VSV) Delta G-based vaccine candidates, expressed in Vero cells, from their current overseas production facilities to domestic Contract Development and Manufacturing Organizations (CDMOs).   This ambitious project involves complete tech transfer of current vaccine production processes, including: • Bulk drug substance manufacturing • Drug product formulation and fill/finish operations • Manufacturing under BSL-2 and cGMP conditions • Analytical method transfer and validation • Engineering runs and metrics validation to ensure process equivalence   Given the complexity of VSV-based vaccine manufacturing, teaming arrangements are strongly encouraged between product sponsors, tech owners, CDMOs, and government stakeholders.   𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝗗𝘂𝗲: November 12, 2025 𝗣𝗿𝗼𝗽𝗼𝘀𝗮𝗹𝘀 𝗗𝘂𝗲: December 11, 2025   𝗡𝗼𝘁𝗲: BioMaP-Consortium membership is required to be eligible for proposal submission.   This initiative represents a crucial step toward strengthening America's biodefense capabilities and ensuring rapid response capacity for future viral hemorrhagic fever outbreaks.   Learn more: https://lnkd.in/gqd99tEG Stay up to date on all things MILMED R&D >> https://lnkd.in/gndVzFQE   #BioMaP #BARDA #Vaccines #Filovirus #MILMEDConnect

🌍 Global Biotechnology Vaccine Market – October 2025 Insights 🌍 The global vaccine market is accelerating at an unprecedented pace! With projected growth from $91.97B in 2025 to $161.4B by 2034, driven by mRNA & recombinant vaccines, preventive healthcare awareness, and expanding immunization programs, the landscape has never been more dynamic. 💡 Top Players Leading the Market: Merck & Co. – Expanding production with new facilities Pfizer – Dominating the U.S. vaccine market GSK – Strong seasonal flu portfolio Sanofi – Regulatory scrutiny in EU, but major player Moderna – Pioneering mRNA vaccines globally Johnson & Johnson – Broad vaccine pipeline 🔍 SWOT Analysis Highlights: Strengths: Innovative technology, global immunization programs, strong R&D pipelines Weaknesses: Regulatory hurdles, supply chain challenges Opportunities: Emerging markets, adult vaccination, new vaccine developments Threats: Vaccine hesitancy, antitrust investigations 🚀 Key Takeaway: The vaccine market offers immense growth opportunities, especially in emerging markets and adult immunization programs. Companies that innovate and navigate regulatory complexities will lead the next decade of healthcare transformation. #Vaccines #Biotechnology #PharmaInnovation #GlobalHealth #mRNA #RecombinantVaccines #HealthcareTrends #Immunization #EmergingMarkets #BiotechLeadership

⚡ The Blueprint That Could Fix the Vaccine Bottleneck For months, I’ve been studying where we fell short not scientifically, but structurally. How something as life-saving as a vaccine could take years to scale, not because we lack knowledge, but because the systems between discovery and deployment are fractured, siloed, and paper-based. So, I built a new one. It’s called the Modular Respiratory Vaccine Platform (MRVP) a 90-day executable blueprint designed under my WattsProtect™ Governance Framework. It shows how the world can move from concept to large-scale vaccine readiness in a single quarter, using digital traceability, real-time assay integrity, and modern manufacturing logic. This isn’t theory. It’s fully scoped, costed, regulator-aligned, and ready for BARDA, HHS, Novavax, Thermo Fisher, Lonza, or any partner with courage to execute. ✅ What it does: • Transitions production from insect-cell systems to scalable CHO/yeast biomanufacturing. • Substitutes rare natural adjuvants with synthetic GMP analogs for stability and equity. • Externalizes assays to FDA-audited CROs for purity and potency verification. • Digitally chains every step through WattsProtect™ — creating a live, tamper-proof record of trust. • Compresses manufacturing and validation from 18 months to 90 days. ✅ Why it matters: Because public health cannot rely on chance, outdated processes, or invisible data. This blueprint creates evidence certainty — the same standard I’ve been fighting for in law, AI, and governance. ✅ Who I’m offering it to: Any national or global entity prepared to build a transparent, accountable, and humane vaccine future. That includes Novavax, Thermo Fisher Scientific, Lonza , Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response and U.S. Department of Health and Human Services (HHS) — as well as every independent scientist or policymaker who knows that the next pandemic demands more than another patchwork system. This is not a company pitch. It’s a call to restore integrity in biomanufacturing to prove that speed, safety, and truth can coexist. The full Executable Deployment Blueprint (WattsProtect™ Edition) is now complete and public. If you’re in government, biotech, or defense innovation I invite you to read it, share it, and contact me. The question is no longer can we do it? It’s why haven’t we already? — Andre Jason Watts Inventor | WattsProtect™ Governance System Advancing Digital Integrity in Public Health, AI, and Law Medha Raina, PhD Yingwen H. Robert Koogle Jonathan Yasosky, Ph.D.

🗞️ “Universal” doesn’t have to mean complicated. ReNewVax Ltd features in a new online article published in Drug Discovery World, discussing how we rethink the design, manufacture, and scaling of vaccines to combat an ever-wider range of health challenges, including bacterial threats like #StreptococcusPneumoniae. 💡With over 100+ serotypes and growing antimicrobial resistance, urgent solutions are needed. Our answer?🧬 Our lead candidate, #RVX‑001, which is designed not only to protect against all known strains of pneumococcus, but also be inexpensive to manufacture at scale. We’re pleased to be part of this feature on how next-gen platforms are helping vaccines go further, faster, and fairer. 🔍 Learn more about how we're reshaping the future of pneumococcal vaccination https://lnkd.in/efWPQRY5 👉 Read the full article: https://lnkd.in/e2wZifPw #ReNewVax #Vaccines #UniversalVaccine #ProteinVaccine #Pneumonia #AMR

🌟 Advancements in Pertussis Vaccination: Optimizing Cationic Lipid-Based Adjuvants 🌟 I’m thrilled to share highlights from a recent study by Tavonga T. Mandava and colleagues that focuses on the design and evaluation of a novel cationic lipid nanoparticle-based pertussis vaccine. This research is pivotal in addressing the resurgence of pertussis cases globally, especially among vulnerable populations. 🔬 Key Insights: Innovative Approach: The study employed a Design-of-Experiments (DoE) methodology to optimize the lipid composition of a triple adjuvanted vaccine (L-TriAdj), enhancing its physicochemical properties and immunogenicity. Enhanced Immune Response: Results indicated that increasing the alkyl chain length of phosphatidylcholine lipids significantly improved cellular viability, uptake, and the induction of critical cytokines like IL-12 and IFN-γ. Importance of Lipid Composition: The findings underscore that varying the ratio of phosphoethanolamine and phosphatidylcholine lipids influences vaccine performance, with specific formulations leading to robust immune responses. 💡 Conclusion: This research not only provides valuable insights into the formulation of effective pertussis vaccines but also emphasizes the critical role of lipid composition in vaccine efficacy. Moving forward, in vivo studies will be essential to validate the protective capacity of these optimized formulations. Let's continue to innovate and improve our vaccine strategies for better public health outcomes! 💉✨ https://lnkd.in/eX9j-q_N #Vaccines #Immunology #CationicLipids #Pertussis #PublicHealth #Pharmaceuticals #Research

Microneedle-Based Transdermal Systems for Vaccines and Biologics: A Review by Mohammad Azmath Hussain srinivasarao mande Read full Article: https://lnkd.in/dn5FYEB3 #Microneedledeliverysystems #Transdermalvaccination #Biologics #Minimallyinvasivedrugdelivery #Immunization #Patientcompliance #Vaccinestability

Recently I was doing scientific analyze of different vaccines, for my own development, being curious about this part of medicine, i was not so much in throughout my career. And found quite interesting things about Pneumococcal infections and vaccines against them. May be it is obvious for professionals and experts in this area, but from the point of view of clinical trials it was interesting to discover (for myself, for sure) the trend. Main struggle against IPDs (invasive pneumococcal diseases) started 20-30 years ago, when pneumococcal polysaccharide conjugate vaccines (PCVs) were developed globally by several pharma companies (first PCVs were made much earlier in 70th like PCV4 but main struggle was started later). First it was quite a few amount of serotypes in PCVs, which was reflected in its numbering - PCV7, PCV13, PCV16 etc. But later closer to current days - several pharma companies already registered vaccines like PCV20, PCV21. Now there are several trials ongoing where the very progressive high-end vaccines are under research - PCV26 and even PCV31. And that is fantastic development. However, I need to say, that generally there are about 100 (!) wild serotypes of Pneumacoccal infections existing in nature. Quite a lot, and we only now meeting the 1/4 of all serotypes numbers in our vaccines. There are a lot of reasons why, reasons what serotypes are included into PVCs and how it goes. But returning back to my own conclusion i got from all that research I was doing, reading many articles, study details and analytical reviews - this is all the race against time! Cause earlier researches found interesting trend - invention of vaccines with higher index (meaning PCV20, PCV30 etc) doesnt lead to win of humanity over IPDs but just partial success, because nature IMMEDIATELY replaces part of the vaccine serotypes (VT) by non-vaccine serotypes (NVT) in the pattern of morbidity globally. Obviously that race against time (human, and their vaccines against nature with her ~100 serotypes) possibly will end when humanity invents smth like "PCV100". But the issue here is in technology: results of the complexity of conjugate vaccine manufacturing, because only a fraction of these are currently included in the pneumococcal polysaccharide conjugate vaccines. In other words - we cannot do "PCV100" now, until we find proper carrier or vector to create that "PCV100". I wish all the researchers and companies success in this area, because this is THE VERY important area of medicine and struggles against disease, which may be fatal in many cases. Especially nowadays, when we have antibiotic resistent strains of bacterias, resistent serotypes and etc. Anyway it is very interesting to follow this topic and see how pharma industry develops. And be inside, doing clinical trials as professional makes me proud, being in the very edge of science and healthcare! #vaccines #virology #pneumococcaldiseases #clinicaltrials #modernapproach #PCV #opentowork

💉 Hepatitis A Vaccine Market to Reach USD 1,026.97 Million by 2031 📈 The global Hepatitis A Vaccine Market was valued at USD 791 Million in 2024 and is projected to reach USD 1,026.97 Million by 2031, growing at a CAGR of 3.8% during 2025–2031. 📊 Key Growth Drivers ✅ Rising awareness about hepatitis prevention and vaccination programs ✅ Growing government immunization initiatives across developing nations ✅ Increasing prevalence of hepatitis A infections globally ✅ Continuous R&D efforts to develop improved vaccine formulations GSK | Merck | Sanofi | Sinovac | Zhejiang Pukang | Changchun Institute of Biological | KM Biologics | IMBCAMS | Convac https://lnkd.in/dNfZ8E9Q 🧩 Product Segments Inactivated Vaccine Live Attenuated Vaccine 🏥 Applications Government Institutions Private Sector Others #HepatitisA #VaccineMarket #HealthcareIndustry #PublicHealth #Vaccination #Pharmaceuticals #Biotechnology #InfectiousDiseases #GlobalHealth #MarketGrowth